HCPLive

AUGUST 31, 2024

RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.

Quality of Life 64

Quality of Life Bicuspid/Mitral Heart Failure Hospital 64

DAIC

FEBRUARY 21, 2024

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. Other symptoms include swelling in the abdomen, legs or neck veins.

Heart Failure 105

Heart Failure Open-Heart Surgery Tricuspid Heart Disease 105

American College of Cardiology

DECEMBER 10, 2024

The RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: Second Trial in Patients With Clinically Significant Functional Mitral Regurgitation) trial was an international, open-label, multicenter, randomized controlled trial designed to provide additional information regarding the safety and effectiveness of M-TEER in this (..)

Bicuspid/Mitral 48

Bicuspid/Mitral Heart Failure Article 48

Med Page Today

AUGUST 31, 2024

(MedPage Today) -- LONDON -- Despite another positive trial, controversy rages on over transcatheter edge-to-edge repair (TEER or M-TEER) in people with symptomatic heart failure (HF) and functional mitral regurgitation (MR). All three primary.

Bicuspid/Mitral 59

Bicuspid/Mitral Heart Failure 59

American College of Cardiology

AUGUST 31, 2024

The goal of the RESHAPE-HF2 trial was to assess the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 46

Bicuspid/Mitral Heart Failure Article 46

American College of Cardiology

AUGUST 31, 2024

The goal of the MATTERHORN trial was to evaluate mitral transcatheter edge-to-edge repair (M-TEER) compared with surgical mitral valve repair among patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 46

Bicuspid/Mitral Heart Failure Article 46

Open Heart

DECEMBER 7, 2023

Objectives Prognostic impact of lung ultrasound-derived B-lines (LUS-BL) in heart failure with mildly reduced left ventricular ejection fraction (HFmrEF) patients remains elusive. to 2.94), increased ratio of early transmitral flow velocity to early mitral annular velocity (>24, HR=1.79, 95% CI 1.11

Ultrasound 98

Ultrasound Heart Failure Risk Factors Bicuspid/Mitral 98

The American Journal of Cardiology

DECEMBER 13, 2023

Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): Esther Munerato Figueira da Silva, Raquel Martins Loureiro, Renan Shida Marinho, Júlia Marioti, Samuel Sá, Gabriela Pereira Gil Castilho, Guilherme Casale, Audrey Borghi Silva, Carlos Henrique de Freitas Lima, Meliza Goi Roscani

Heart Failure 98

Heart Failure Bicuspid/Mitral Exercise 98

CardiacWire

JULY 28, 2024

Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.

Heart Failure 59

Heart Failure Aortic TAVR Critical Care 59

DAIC

FEBRUARY 20, 2024

The Intrepid TMVR is a heart valve that is designed to help alleviate mitral regurgitation so that blood can flow through the heart in the intended direction,” said Matthew Saybolt , M.D., FACC, principal site investigator and medical director, Structural Heart Disease Program, Jersey Shore University Medical Center.

Heart Valves 116

Heart Valves Bicuspid/Mitral Academic Chest Pain 116

American College of Cardiology

NOVEMBER 5, 2024

The goal of the COAPT trial was to assess the safety and efficacy of transcatheter mitral leaflet approximation using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 40

Bicuspid/Mitral Heart Failure Outcomes Article 40

European Journal of Heart Failure

APRIL 17, 2024

HFpEF, heart failure with preserved ejection fraction; MR, mitral valve regurgitation. Abstract Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Bicuspid/Mitral Heart Failure Pulmonary 40

European Journal of Heart Failure

FEBRUARY 26, 2025

Proposed approach for clinical management and therapeutic optimization in patients with heart failure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.

Blood Pressure 58

Blood Pressure Heart Failure Aortic valve TAVR 58

CardiacWire

JUNE 21, 2024

Columbia and Cornell researchers developed an echo AI model that could improve the difficult task of mitral regurgitation diagnosis, and might even represent an AI-driven step towards enhancing all valvular regurgitation assessments. The post New Echo AI Model Could Streamline Mitral Regurgitation Diagnosis appeared first on Cardiac Wire.

Bicuspid/Mitral 59

Bicuspid/Mitral Research Academic Heart Failure 59

American College of Cardiology

DECEMBER 16, 2024

Transcatheter edge-to-edge repair (TEER) and mitral valve (MV) surgery (both replacement and repair) are two approaches for managing patients with heart failure (HF) and secondary mitral regurgitation (MR).

Bicuspid/Mitral 43

Bicuspid/Mitral Heart Failure Article 43

DAIC

JUNE 11, 2024

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

Tricuspid 52

Tricuspid Bicuspid/Mitral Heart Valves Innovation 52

Heart BMJ

DECEMBER 13, 2024

Secondary mitral regurgitation (SMR) is a complex and evolving challenge in the landscape of heart failure (HF) management. Or should we adopt an integrated approach, incorporating early mitral valve intervention, especially for patients with persistent symptoms despite.

Pharmacology 52

Pharmacology Bicuspid/Mitral Heart Failure Outcomes 52

European Journal of Heart Failure

DECEMBER 11, 2024

Abstract Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock.

Cardiogenic Shock 68

Cardiogenic Shock Heart Disease Heart Failure Bicuspid/Mitral 68

DAIC

JANUARY 8, 2024

milla1cf Mon, 01/08/2024 - 14:35 January 8, 2024 — University Hospitals (UH) Harrington Heart & Vascular Institute recently became the first center in the world to implant Medtronic’s Penditure Left Atrial Appendage (LAA) Exclusion System through a minimally invasive approach during a mitral valve repair procedure.

Bicuspid/Mitral 124

Bicuspid/Mitral Atrial Fibrillation Anatomy Coronary Artery Disease 124

The New England Journal of Medicine

NOVEMBER 13, 2024

Functional mitral regurgitation is a disease of the left heart as opposed to the valve leaflets themselves. Two thirds of patients with heart failure have moderate or severe functional mitral regurgitation.1

Bicuspid/Mitral 40

Bicuspid/Mitral Heart Failure 40

Frontiers in Cardiovascular Medicine

JANUARY 14, 2024

Background Echocardiography-guided percutaneous intramyocardial alginate-hydrogel implantation (PIMAHI) is a novel treatment approach for heart failure (HF). We validated PIMAHI safety and efficacy in canine HF models. Compared with controls at 6-month, PIMAHI group significantly increased LVFW thickness (8.5 ± 0.3 vs. 6.8 ± 0.2 mm,

Heart Failure 64

Heart Failure Outcomes Bicuspid/Mitral Arrhythmia 64

DAIC

JUNE 5, 2024

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.

Critical Care 105

Critical Care Tricuspid Innovation Bicuspid/Mitral 105

DAIC

FEBRUARY 15, 2024

Advances in Transcatheter Tricuspid Valve Technologies VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.

Tricuspid 102

Tricuspid Heart Valves Quality of Life Bicuspid/Mitral 102

HeartRhythm

APRIL 30, 2024

The development of AF is an indication for surgical mitral valve replacement in patients with severe mitral regurgitation. However, some patients only experience arrhythmia episodes without other indications, such as decreased ejection fraction or heart failure.

Bicuspid/Mitral 40

Bicuspid/Mitral Atrial Fibrillation Heart Failure Ablation 40

Circulation

NOVEMBER 11, 2024

All-cause hospitalization (HR: 2.31, 95%CI: 2.04 – 2.62, p&lt;0.001), heart failure hospitalization (HR: 2.22, 95%CI: 1.92 – 2.55, p&lt;0.001), acute myocardial infarction (HR: 2.06, 95%CI: 1.79 – 2.35, p&lt;0.001), unstable angina (HR: 2.28, 95%CI: 1.72-3.04, vs non-MAC (58.2 + 12.6).

Heart Failure 40

Heart Failure Preserved Ejection Fraction Bicuspid/Mitral Outcomes 40

Dr. S. Venkatesan MD

OCTOBER 11, 2024

In the process, improving the ejection fraction and possibly reducing mitral regurgitation. However, advanced heart failure therapy never means it can be achieved only by state-of-the-art technology. Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure. 2021 May 21;23(5):740-747. Reference 1.

Heart Failure 59

Heart Failure Ultrasound Anatomy Technology 59

Circulation: Cardiovascular Interventions

JANUARY 18, 2024

BACKGROUND:Limited data exist regarding the impact of mitral annular calcification (MAC) on outcomes of transcatheter edge-to-edge repair for mitral regurgitation (MR).METHODS:We Circulation: Cardiovascular Interventions, Ahead of Print. with functional MR) who underwent an isolated, first-time intervention. versus 9.6%;P=0.016;

Bicuspid/Mitral 40

Bicuspid/Mitral Outcomes Heart Failure Echocardiogram 40

Circulation

NOVEMBER 11, 2024

EECP can improve exercise tolerance, reduce anginal symptoms, and enhance endothelial function, offering a potential alternative for patients with ischemic HFrEF awaiting heart transplantation.Description of a Case:A 58-year-old Hispanic female with a history of severe CAD, type II DM, hyperlipidemia, and CVA.

Heart Transplant 75

Heart Transplant Transplant Angina Heart Failure 75

European Journal of Heart Failure

FEBRUARY 19, 2025

Prognostic impact of severe tricuspid regurgitation (TR) in patients with atrial functional mitral regurgitation (AFMR). Abstract Aims Tricuspid regurgitation (TR) is often seen in patients with atrial functional mitral regurgitation (AFMR). The primary endpoint was a composite of heart failure hospitalization and all-cause mortality.

Tricuspid 40

Tricuspid Bicuspid/Mitral Atrial Fibrillation Heart Failure 40

DAIC

JANUARY 16, 2024

Dr. Shreenivas brings his rich experience in both the clinical and commercial aspects of the structural heart landscape to his new role with Cardiac Dimensions. There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies.

Bicuspid/Mitral 59

Bicuspid/Mitral Heart Failure Catheterization Laboratory Innovation 59

Journal of Cardiothoracic Surgery

JANUARY 19, 2024

We present a patient with a history of heart failure and metallic aortic and mitral valves surgeries, who required ablation for a drug-refractory left ventricular tachycardia. But the metallic valves prohibite.

Bicuspid/Mitral 40

Bicuspid/Mitral Tachycardia Aortic Ablation 40

Heart BMJ

SEPTEMBER 16, 2024

Clinical introduction A woman in her 30s, a case of rheumatic mitral stenosis status post balloon mitral valvuloplasty 15 years prior, presented to urgent care with palpitations and dyspnoea for 1 week. She was noted to be in heart failure, with hypotension and tachycardia.

Atrial Flutter 52

Atrial Flutter Bicuspid/Mitral Heart Failure Tachycardia 52

Circulation: Cardiovascular Imaging

MARCH 21, 2025

Severe mitral regurgitation (MR) also causes a low-flow state, adding complexity to diagnosis and management. BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction.

Stenosis 40

Stenosis Aortic Aortic valve Bicuspid/Mitral 40

DAIC

JULY 17, 2024

Procedures that leverage transseptal delivery include atrial fibrillation ablation , patent foramen ovale (PFO) and atrial septal defect (ASD) repair, percutaneous mitral valve repair, left atrial appendage closure, and percutaneous left ventricular assist device placement, among others. billion by the end of 2033.

Myocardial Infarction 105

Myocardial Infarction Atrial Fibrillation Technology Angina 105

Journal of the American Heart Association

FEBRUARY 23, 2024

Journal of the American Heart Association, Ahead of Print. We sought to examine the prognostic value of combining predischarge MR, TR, and TMPG to study long‐term outcomes after TEER.Methods and ResultsWe reviewed the records of 291 patients who underwent successful mitral TEER at our institution between March 2014 and June 2022.

Bicuspid/Mitral 40

Bicuspid/Mitral Outcomes Risk Factors Tricuspid 40

American College of Cardiology

APRIL 26, 2024

Transcatheter mitral valve-in-ring (MViR) using third-generation balloon-expandable aortic transcatheter heart valves was associated with a significant reduction in mitral regurgitation (MR) and improvement in heart failure symptoms at one year, with the tradeoff of elevated valvular gradients and a high rate of reintervention, according to a recent (..)

Bicuspid/Mitral 48

Bicuspid/Mitral Heart Valves Cardiovascular Interventions Heart Failure 48

Circulation

JANUARY 20, 2025

Circulation, Volume 151, Issue 3 , Page e27-e27, January 21, 2025.

Article 45

Article Heart Failure Bicuspid/Mitral Circulation 45